Study of Bcl-2 Inhibitor Sonrotoclax (BGB-11417) in Participants With Mature B-Cell Malignancies
Public ClinicalTrials.gov record NCT04277637. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1a/1b Open-Label Dose Escalation and Expansion Study of Bcl-2 Inhibitor BGB-11417 in Patients With Mature B-Cell Malignancies
Study identification
- NCT ID
- NCT04277637
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- BeOne Medicines
- Industry
- Enrollment
- 437 participants
Conditions and interventions
Conditions
Interventions
- Obinutuzumab Drug
- Sonrotoclax Drug
- Zanubrutinib Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 23, 2020
- Primary completion
- May 30, 2027
- Completion
- May 30, 2027
- Last update posted
- Mar 26, 2026
2020 – 2027
United States locations
- U.S. sites
- 13
- U.S. states
- 12
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UCLA Hematologyoncology | Los Angeles | California | 90095-3075 | — |
| Northwestern University | Chicago | Illinois | 60611 | — |
| University of Kansas Medical Center Research Institute | Kansas City | Kansas | 66160-8500 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| Mayo Clinic Rochester | Rochester | Minnesota | 55905-0001 | — |
| University of Nebraska Medical Center | Omaha | Nebraska | 68198 | — |
| John Theurer Cancer Center Hackensack University Medical Center | Hackensack | New Jersey | 07601-2191 | — |
| Columbia University Medical Center | New York | New York | 10032 | — |
| Memorial Sloan Kettering Cancer Center Mskcc | New York | New York | 10065-6800 | — |
| The James Cancer Hospital and Solove Research Institute At Ohio State University | Columbus | Ohio | 43210-1240 | — |
| Upmc Hillman Cancer Center(Univ of Pittsburgh) | Pittsburgh | Pennsylvania | 15232-1309 | — |
| Md Anderson Cancer Center | Houston | Texas | 77030-3907 | — |
| Fred Hutchinson Cancer Research Center | Seattle | Washington | 98109-4433 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 30 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04277637, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 26, 2026 · Synced May 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04277637 live on ClinicalTrials.gov.